30 closest matches · ranked by relevance
Brain and Central Nervous System Tumors
Primary: Progression-Free Survival (PFS) in ERBB2-Negative Tumors Compared to ERBB2-Positive Tumors — 79.2; 83.3; 69.6; 86.7 probability of PFS at 2 years — p=0.8001
Brain and Central Nervous System Tumors
Primary: Feasibility
Medulloblastoma · Neuroectodermal Tumor
Primary: 12 Month Progression-free Survival (PFS-12) — 215; 69 Days — p=0.927
Adult Medulloblastoma
Primary: Objective Response (CR+PR) Sustained for ≥ 8 Weeks — 0; 0.15; 0 proportion of participants
Metastatic Medulloblastoma · High Risk Supratentorial PNET · Metastatic PNET
Primary: Event-free Survival — 7 Participants
Desmoplastic/Nodular Medulloblastoma · Medulloblastoma · Medulloblastoma With Extensive Nodularity
Primary: Progression-free Survival (PFS) — 52.0 percent probability
Central Nervous System Neoplasm · Pineoblastoma · Recurrent Medulloblastoma
Primary: Overall Survival — 2.43; 13.6 percent probability
Recurrent Childhood Medulloblastoma
Primary: Objective Response (CR+PR) Sustained for ≥ 8 Weeks — 1 participants
Anaplastic Medulloblastoma · Medulloblastoma · Supratentorial Embryonal Tumor, Not Otherwise Specified
Primary: Number of Patients Who Have Either a Complete Response (CR) Rate or No Complete Response Rate — 13; 15; 16; 15 Participants — p=0.35
Brain Tumor · Brain Metastases
Primary: Affects of Response Rate of Chemotherapy With Intra-arterial Carboplatin and Oral Temozolomide — 42.8 percentage of patients with response
Neuroblastoma
Primary: Overall Response Rate [Complete Response + Very Good Partial Response + Partial Response (CR + VGPR + PR)] — 42 Participants
Brain and Central Nervous System Tumors · Long-term Effects Secondary to Cancer Therapy in Children
Primary: Cumulative Incidence of Ototoxicity — 12; 16; 16; 15 percentage of participants
Medulloblastoma · Rhabdomyosarcoma · Neuroblastoma
Primary: Number of Participants With Dose-limiting Toxicities (DLT) in Phase I — 0; 1; 0; 0 participants
Medulloblastoma
Primary: Percentage of Participants With Overall Response Rate (ORR) According to Independent Review Committee (IRC) From Date First Participant Randomized, 13-Sep-2013 to Date…
Medulloblastoma
Primary: Event-free Survival (EFS) — 76.3; 84.9; 85.8; 85.8 probability of 3 year EFS
Central Nervous System Neoplasms · Medulloblastoma
Primary: Percentage of Participants With an Objective Response and Long-term Stable Disease — 0; 11.1; 10.5; 0 percentage of participants
Central Nervous System Tumor, Pediatric · Neuroblastoma
Primary: Therapy Completion Rate — .40 proportion of participants
Ganglioneuroblastoma · Stage 1 Neuroblastoma · Stage 2 Neuroblastoma
Primary: The Tolerability of BuMel Regimen — 9 participants
Brain Tumor · Medulloblastoma · Pineoblastoma
Primary: Cumulative Incidence of Ototoxicity — 26; 27 percentage of participants
Glioblastoma Multiforme · Anaplastic Astrocytoma · Anaplastic Oligodendroglioma
Primary: Number of Patients Who Experienced Dose-limiting Toxicities (DLTs) — 3 Participants
Central Nervous System Tumors
Primary: Measurement of Number of Adverse Events — 4; 6; 3; 5 Adverse events
Adult Rhabdomyosarcoma · Lung Metastases · Metastatic Ewing Sarcoma
Primary: Feasibility of Delivering Cardiac-sparing IMRT With Central Quality Control in 20 Subjects — 20 Participants
Neuroblastoma
Primary: Response (Complete Response, Very Good Partial Response, and Partial Response) at 60-days Post Stem Cell Infusion — 4; 3 participants
Neoplasm Metastasis
Primary: Percent of Participants With Locoregional Control of Treating Brain Metastasis Patients — 92; 98.6; 46; 46 percentage of participants
Metastatic Bone Tumor
Primary: Overall Survival (OS) — 21.5; 12.7; 26.6 months
Brain Cancer
Primary: Number of Participants With High-grade Astrocytoma and Diffuse Pontine Tumors Achieving One Year Progression Free Survival. — 5; 6 Participants
Neuroblastoma
Primary: Maximum Tolerated Dose — 18.6 mCi/kg
Brain Tumor · Central Nervous System Tumors · Childhood Germ Cell Tumor
Primary: Response to Induction Chemotherapy — 74; 11 Participants
Neuroblastoma · Medulloblastoma · Relapse
Primary: Number of Participants With Adverse Events as a Measure of Safety and Tolerability — 14 participants
Lung Cancer, Non-Small Cell
Primary: Overall Survival — 4.0; 3.6 months — p=0.1862